Earlier genetic testing in men with very low sperm counts may spare unnecessary testing or surgery, according to Ronald Anglade, MD.
|Videos|August 19, 2022
Experts discuss testosterone deficiency in obese men desiring fertility
Among the topics touched on in the discussion are lifestyle considerations, medical therapy, and surgical options.
Advertisement
In this expert panel video, Darshan P. Patel, MD, Kevin J. Campbell, MD, MS; Kelli Gross, MD; Mary K. Samplaski, MD; and James M. Hotaling, MD, MS, discuss the case of a 37-year-old obese man who presents with low libido and infertility.
Advertisement
Related to this article
Vignesh Packiam, MD, discusses optimizing BCG treatment in high-risk NMIBC, including patient selection for combination immunotherapy and treatment-related trade-offs.
Suzanne B. Merrill, MD, discusses emerging perioperative approaches in MIBC and the potential for more personalized treatment selection based on disease characteristics.
Benjamin Garmezy, MD, discusses personalizing mHSPC treatment intensification based on disease burden, molecular biomarkers, and patient-specific factors.
William Huang, MD, discusses histotripsy for renal tumors, the #HOPE4KIDNEY trial, and the technology’s potential to preserve kidney function.
Alicia Morgans, MD, discusses ARACOG findings on cognitive outcomes with darolutamide vs enzalutamide and the influence of genetic dementia risk.
Elie Kaplan-Marans, MD, discusses geographic disparities in reproductive urology access and how workforce gaps may affect comprehensive infertility evaluations.
Aaron Berger, MD, discusses patient selection for ARPI treatment holidays, monitoring during interruptions, and the role of testosterone recovery in interpreting PSA kinetics.
Advertisement
Advertisement
Trending on Urology Times
1
American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
2
FDA grants De Novo authorization to Virtuoso Robotic System for bladder tumor resection
3
BCG-naïve NMIBC: Optimizing initial treatment selection
4
FDA grants breakthrough therapy designation to 64Cu-SAR-bisPSMA for recurrent prostate cancer imaging
5